GSK's Shingrix Vaccine Gets FDA Approval for Prefilled Syringe
Why we think this is neutral
The RNS announcement provides an update on the FDA approval of a new prefilled syringe presentation of GSK's Shingrix vaccine, which simplifies the administration process for healthcare professionals. While this is a positive development, the announcement does not contain any financial figures, trading updates, or other mandatory news types that would warrant a stronger sentiment score.
Key Points
- FDA approval for prefilled syringe presentation of GSK's Shingrix vaccine
- New presentation simplifies administration process for healthcare professionals
- Shingrix is approved for adults aged 50+ and those at increased risk of shingles
Summary
GSK has received FDA approval for a prefilled syringe presentation of its Shingrix vaccine, which removes the need for healthcare professionals to reconstitute separate vials prior to administration. The new presentation is expected to provide a more convenient option for administering the shingles vaccine. Shingrix is approved in the US for immunisation of adults aged 50 years and older, as well as those aged 18 years and older who are or will be at increased risk of shingles due to immunodeficiency or immunosuppression.